VistaGen Therapeutics, Inc.
384 Oyster Point Boulevard
Suite 8
South San Francisco
California
94080
United States
Tel: 650-244-9990
Fax: 650-244-9979
Website: http://www.vistagen.com/
Email: rsnodgrass@vistagen.com
162 articles with VistaGen Therapeutics, Inc.
-
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder
7/23/2020
Company Reaches Consensus with FDA on Key Aspects of Novel Pivotal Phase 3 Study Agency Guidance May Provide Significant Time- and Cost-Efficiency for Phase 3 Program Approximately 17 Million American Adults Suffer from Social Anxiety Disorder [23-July-2020]
-
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
6/29/2020
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results for its fiscal year ended March 31, 2020.
-
VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia
6/25/2020
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets Agreement includes $5 million upfront payment and development and commercial milestones up to $172 million
-
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
5/27/2020
Novel Cocrystal Form of AV-101 Administered with Probenecid May Have Superior Delivery, an Enhanced Therapeutic Profile and Additional Intellectual Property Protection [27-May-2020] SOUTH SAN FRANCISCO, Calif. , May 27, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiet
-
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
5/18/2020
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
-
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
4/28/2020
Proposed Phase 2 Study to Take Place in New York City Under U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
-
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
3/25/2020
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical need, today announced a common stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC),
-
Clinical Catch-Up: February 17-21
2/24/2020
Mid-February had a solid number of clinical trial announcements. Here’s a look. -
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
2/20/2020
PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy
-
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
2/13/2020
VistaGen Therapeutics announced financial results for its fiscal year 2020 third quarter ended December 31, 2019.
-
VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects
2/11/2020
When given together with VistaGen's oral prodrug AV-101, probenecid increased brain concentrations of AV-101 7-fold and its active metabolite, 7-CI-KYNA, 35-fold
-
Clinical Catch-Up: January 27-31
2/3/2020
It was another busy week for clinical trial updates. Here’s a look. -
VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients
1/30/2020
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced that its Investigational New Drug (IND) application for AV-101, the Company's oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist
-
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
12/10/2019
VistaGen's PH94B is the first drug candidate to be granted U.S. FDA Fast Track designation for treatment of social anxiety disorder
-
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
11/14/2019
VistaGen Therapeutics announced topline results from the ELEVATE study, a Phase 2 study of AV-101, its NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive treatment of major depressive disorder (MDD).
-
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
11/7/2019
VistaGen Therapeutics, a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet need, announced financial results for its fiscal year 2020 second quarter ended September 30, 2019.
-
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
10/28/2019
The patent will be in effect until at least 2034.
-
VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
10/8/2019
VistaGen Therapeutics announced that the last patient has completed dosing in the ELEVATE Phase 2 clinical study of AV-101, the Company's novel, oral NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive (add-on) treatment with an FDA-approved oral antidepressant for major depressive disorder (MDD).
-
When major depressive disorder (MDD) does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it is reclassified as treatment-resistant depression or TRD. South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet its pr...